Published in Hepatitis Weekly, April 7th, 2003 That is what
happened to children enrolled in a prospective open trial to
treat chronic hepatitis B infections with lamivudine, according
to Corina Hartman and colleagues at Meyer Children's Hospital of
Haifa in Haifa, Israel. Each of the 20 children, aged 8.5 to 19
years, had previously received interferon, a standard therapy
for chronic hepatitis B, and none had responded to that
treatment. "At the end of 1 year, HBV... Want to see the full
article? Welcome to NewsRx! Learn more about a six-week, no-risk
free trial of Hepatitis Weekly NewsRx also is available at
LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters,
NewsEdge, and Dow Jones.